“…To prevent this, several techniques were developed, such as, for example, the incorporation of a charged moiety: either positive 144–148 or negative. 149,150 ZnPcs can also be encapsulated in cyclodextrins, 151 liposomes, 152–154 micelles, 155–158 or nanoparticles (that can consist of polymers, 159–161 silica, 162,163 gold, 164,165 or TiO 2 166 ). Two ZnPcs were or are already in phase II clinical trials: CGP55847, which is a liposomal formulation of ZnPc, used against squamous cell carcinomas, 167 and photocyanine, a di-(potassium sulfonate)-di-phthalimidomethyl ZnPc which was under clinical trial in China against human hepatocellular carcinoma up to phase II (Fig.…”